

# Genomic Epidemiology: Objectives of genomic data in enhancing surveillance activities

**Laboratory Response Team  
PAHO-IMST  
Health Emergencies Department**






# Molecular Epidemiology

## Background and definitions

- **Epidemiology** aims to study the distribution, determinants, and causes of health-related problems in order to prevent and control them effectively.
- **Molecular Epidemiology** integrates the use of techniques and fundamentals of molecular biology (**characterization of nucleic acids** and **amino acid content**), for the study of the distribution (time and place) and determining factors (transmission, manifestations and progression) of the occurrence of a disease

# Molecular Epidemiology

## Molecular bases of change: From the DNA to the proteins




DNA Replication


Errors =  
Mutation

# Molecular Epidemiology

## Molecular bases of change: From the DNA to the proteins



RNA Transcription




Protein Translation

Errors =  
Mutation


# Molecular Epidemiology

## Molecular bases of change: From the DNA to the proteins



### RNA Transcription

Errors =  
Mutation




		U	C	A	G				
		1st base	2nd base	3rd base					
U	UUU	Phenylalanine	UCU	Serine	UAU	Tyrosine	UGU	Cysteine	U
	UUC	Phenylalanine	UCC	Serine	UAC	Tyrosine	UGC	Cysteine	C
	UUA	Leucine	UCA	Serine	UAA	Stop	UGA	Stop	A
	UUG	Leucine	UCG	Serine	UAG	Stop	UGG	Tryptophan	G
C	CUU	Leucine	CCU	Proline	CAU	Histidine	CGU	Arginine	U
	CUC	Leucine	CCC	Proline	CAC	Histidine	CGC	Arginine	C
	CUA	Leucine	CCA	Proline	CAA	Glutamine	CGA	Arginine	A
	CUG	Leucine	CCG	Proline	CAG	Glutamine	CGG	Arginine	G
A	AUU	Isoleucine	ACU	Threonine	AAU	Asparagine	AGU	Serine	U
	AUC	Isoleucine	ACC	Threonine	AAC	Asparagine	AGC	Serine	C
	AUA	Isoleucine	ACA	Threonine	AAA	Lysine	AGA	Arginine	A
	AUG	Methionine (Start)	ACG	Threonine	AAG	Lysine	AGG	Arginine	G
G	GUU	Valine	GCU	Alanine	GAU	Aspartic Acid	GGU	Glycine	U
	GUC	Valine	GCC	Alanine	GAC	Aspartic Acid	GGC	Glycine	C
	GUA	Valine	GCA	Alanine	GAA	Glutamic Acid	GGG	Glycine	A
	GUG	Valine	GCG	Alanine	GAG	Glutamic Acid	GGG	Glycine	G


Nonpolar, aliphatic      Polar, uncharged      Aromatic      Positively charged      Negatively charged

# Molecular Epidemiology

Molecular bases of change:  
From the DNA to the proteins



Genomic changes



Protein changes

- **Molecular Epidemiology** integrates the use of techniques and fundamentals of molecular biology (**characterization of nucleic acids** and **amino acid content**), for the study of the distribution (time and place) and determining factors (transmission, manifestations and progression) of the occurrence of a disease

# Molecular Epidemiology

THE JOURNAL OF INFECTIOUS DISEASES • VOL. 127, NO. 4 • APRIL 1973  
© 1973 by the University of Chicago. All rights reserved.


## SPECIAL ARTICLE

### The Molecular Epidemiology of Influenza

**Edwin D. Kilbourne**

*From the Department of Microbiology, Mount Sinai  
School of Medicine of the City University of  
New York, New York*

# Molecular Epidemiology




**Figure 1.** Profile of major epidemics of influenza in the United States during the 20th century. (○---○) = estimated morbidity in initial wave; (—) = excess annual death rate per 100,000 population. (From data of S. D. Collins. Public Health Monograph no. 48, 1957 and A. D. Langmuir, *In Influenza: Its Epidemiology*. Hospital Practice Vol 6: 103–108, 1971.

"Influenza viruses only present minor antigenic variation during interepidemic period"


In contrast, the pandemic spread of virus in 1947, 1957, and 1968 has been associated with dramatic and radical changes in viral antigenic structure so that, in effect, the global population is presented with a new infective agent—a kind of Andromeda strain<sup>1</sup> to which young and old alike are susceptible.

# Molecular Epidemiology




**Figure 2.** Antigenic variation and pandemic severity of influenza. H = hemagglutinin and N = neuraminidase antigen. Vertical connecting lines indicate antigenic relatedness (i.e., shared antigenic determinants). Double vertical lines indicate close similarity. H<sub>0</sub>N<sub>1</sub> is new subtype designation for A<sub>0</sub>, etc.

- Why does pandemic severity vary?
- Why do pandemics now occur at shorter intervals?
- Whence come the pandemic variants and how thy arise?



**Figure 4.** Different effects of antibodies to hemagglutinin (anti-HA) and neuraminidase (anti-NA) on the development of influenza-virus plaques in monolayer cultures of clone 1-5C-4 cells. Right, plaques in the absence of specific antibody; left, complete plaque inhibition with anti-HA; middle, reduction in plaque size, but not in plaque number, by anti-NA.

# Molecular Epidemiology



**Figure 6.** Presumed structural (molecular) basis for different effects of antibody to hemagglutinin (anti-H) and neuraminidase (anti-NA). Divalent binding of anti-H to virion will neutralize viral attachment and infectivity. For steric reasons anti-NA cannot bind dividentally to single virion but can bridge adjacent virions to aggregate particles (hypothetical).

- *Observation at molecular level:  
Antigen vs Antibody interaction*

**Table 3.** Antigenic variations in hemagglutinin (HA) and neuraminidase (NA) of the virus and pandemic severity of influenza.


Year	Virus		Change in	Extent of change	Result
	H-SW	N1			
1918	H-SW	N1	?	?	Pandemic (severe)
192?	H0	N <sub>1</sub>	HA NA	++ +	No pandemic
1947	H1	N <sub>1</sub>	HA NA	++ +	Pandemic (mild)
1957	H <sub>2</sub>	N <sub>2</sub>	HA NA	+++ +++	Pandemic (severe)
1968	H <sub>3</sub>	N <sub>2</sub>	HA	+++	Pandemic (moderate)

- *Differences in neutralization may impact severity of outbreak*

# Genomic Epidemiology


## First attempts to sequence DNA/RNA

- Robert Holley, 1965: tRNA
- Walter Fiers, 1972: Coat protein gene MS2
- Frederick Sanger, 1977: developed the first DNA sequencing method that utilized radiolabelled partially digested fragments called “chain termination method”



[https://www.google.com/url?sa=i&url=https%3A%2F%2Fregi.tankonyvtar.hu%2Fhu%2Ftartalom%2Ftamop425%2FF0011\\_1A\\_Molekularis\\_medicina\\_en\\_book%2Fch03.html&psig=AOvVaw1\\_lGA1jFopnfulw9Up5sWc&ust=1632598317871000&source=images&cd=vfe&ved=0CAsQjRxqFwoTCPic4e2smPMCFQAAAAAdAAAABAJ](https://www.google.com/url?sa=i&url=https%3A%2F%2Fregi.tankonyvtar.hu%2Fhu%2Ftartalom%2Ftamop425%2FF0011_1A_Molekularis_medicina_en_book%2Fch03.html&psig=AOvVaw1_lGA1jFopnfulw9Up5sWc&ust=1632598317871000&source=images&cd=vfe&ved=0CAsQjRxqFwoTCPic4e2smPMCFQAAAAAdAAAABAJ)

# Genomic Epidemiology




By Aimin Yang, Wei Zhang, Jiahao Wang, Ke Yang, Yang Han and Limin Zhang - [1] doi:10.3389/fbioe.2020.01032, CC BY-SA 4.0, <https://commons.wikimedia.org/w/index.php?curid=101041189>

# Genomic Epidemiology

Genomic epidemiology studies have provided information about infectious diseases:


- causality
- pathogenesis
- circulation patterns
- transmission
- prevention
- therapy



# Genomic Epidemiology

Genomic epidemiology studies have provided information about infectious diseases:

- **causality**
- pathogenesis
- circulation patterns
- transmission
- prevention
- therapy



# Antecedentes Virus Chapare en Bolivia

- Dic 2003 – Ene 2004
  - Conglomerado de casos de fiebre hemorrágica cerca al Rio Chapare en Cochabamba, Bolivia
  - 1 Caso fatal confirmado (hombre de 22 años, cultivador de coca)
    - Sin contacto conocido con otros casos
    - Clínica: fiebre, dolor de cabeza, signos múltiples de hemorragia
      - Muerte 14 días después de inicio de síntomas
    - Por secuenciación, se confirma un virus nuevo: Chapare



# Brote de Fiebre hemorrágica en Bolivia, 2019



## Alerta Epidemiológica Fiebre Hemorrágica por Arenavirus en Bolivia

18 de julio de 2019

En el Estado Plurinacional de Bolivia, se encuentra en curso la investigación de un brote de fiebre hemorrágica causado por un Arenavirus, con casos reportados en personal de salud; ante ello la Organización Panamericana de la Salud / Organización Mundial de la Salud (OPS / OMS) recuerda a los Estados Miembros sobre la necesidad de permanecer vigilantes y fortalecer la implementación de las medidas de prevención y control de infecciones, en todos los niveles de atención en los servicios de salud.

### Resumen de la situación


El 28 de junio de 2019, el Ministerio de Salud del Estado Plurinacional de Bolivia recibió el reporte de 3 casos de síndrome febril hemorrágico de etiología desconocida, con sospecha de transmisión de persona a persona. Hasta el 17

#### Fiebres hemorrágicas por Arenavirus

Son una zoonosis producida por un virus perteneciente al género Arenavirus de la familia de Arenaviridae, asociados generalmente a enfermedades transmitidas por roedores en humanos. Entre los 21 Arenavirus del Nuevo Mundo conocidos, cinco se han vinculado con fiebres hemorrágicas en humanos y dos de ellos en




# Características geográficas del área de exposición de los casos con probable transmisión zoonótica




- Arroz (en Guanay existen 57 pequeños centros de acopio) - Café - otros
- Caranavi a Guanay – 2 horas.

Dr. Joao Toledo; Dra. Alison Paredes,  
OPS/PHE

# Diagnóstico NWA, Bolivia 2019



# Diagnóstico NWA, Bolivia 2019



Different virus than 2002


CDC, Atlanta  
Special Pathogens Branch

New World Arenavirus was  
described: Chapare-2019

# Genomic Epidemiology


Genomic epidemiology studies have provided information about infectious diseases:

- causality
- **pathogenesis**
- circulation patterns
- transmission
- prevention
- therapy




# Genomic Epidemiology

By comparing the genome sequencer of a particular pathogen between severe, fatal or drug resistant cases, it is possible to find out if there is any difference between genomes and identify genetic markers involved




- New type of methicillin-resistant *Staphylococcus aureus* (MRSA) was identified to cause community-acquired MRSA with high fatality rate (*Baba et al., 2002*)
- Comparison of whole genomes from fatal cases and mild cases demonstrated 7 genomic islands responsible for the increased pathogenicity



# Genomic Epidemiology

DENV-2 Asian genotype has been associated to increased risk of Hemorrhagic manifestation



American/Asian genotype (IIIb)

Introduction and replacement around the end of 80's coinciding with the first hemorrhagic cases in Colombia

American genotype (V)

RESEARCH

Open Access


Phylogenetic reconstruction of dengue virus type 2 in Colombia

Jairo A Méndez<sup>1,3\*</sup>, José A Usme-Ciro<sup>2</sup>, Cristina Domingo<sup>4,5</sup>, Gloria J Rey<sup>1</sup>, Juan A Sánchez<sup>3</sup>, Antonio Tenorio<sup>4</sup> and Juan C Gallego-Gómez<sup>2</sup>

# Genomic Epidemiology



Genomic epidemiology studies have provided information about infectious diseases:

- causality
- pathogenesis
- **circulation patterns**
- **transmission**
- prevention
- therapy



# 2012: MERS CoV


B Phylogenetic Tree



Microscopic view of MERS.  
Photo: National Institute of  
Allergy & Infectious Diseases


**Nuevo Virus diferente al  
SARS Co-V**

# CONFIRMED GLOBAL CASES OF MERS-COV 2012 - 2017




# Confirmed global cases of MERS-CoV

Reported to WHO as of 25 Aug 2017 (n=2067)



# Propagación MERS CoV



[https://3.bp.blogspot.com/-S2EhY2APzVo/VXguXjhLBUI/AAAAAAAAD\\_A/yR0GgXn2qx4/s1600/Korea-MERS-Hospitals-and-cases\\_10JUN2015.png](https://3.bp.blogspot.com/-S2EhY2APzVo/VXguXjhLBUI/AAAAAAAAD_A/yR0GgXn2qx4/s1600/Korea-MERS-Hospitals-and-cases_10JUN2015.png)



Pan American  
Health  
Organization




World Health  
Organization  
REGIONAL OFFICE FOR THE Americas


# 2013: Influenza aviar A(H7N9)

ORIGINAL ARTICLE

## Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus



# 2013: Influenza aviar A(H7N9)




Distribución geográfica del linaje asiático Infecciones por virus de la influenza aviar A (H7N9) en humanos informadas a la Organización Mundial de la Salud – China (1 de octubre de 2016 al 7 de agosto de 2017)



Pan American  
Health  
Organization

World Health Organization  
REGIONAL OFFICE FOR THE Americas

# DENV-1 Phylogeny




# DENV-1

American-African  
genotype  
(American sequences)

Central American-North American lineage  
(2005-present)

Point of lineage  
divergence  
1998?



Caribbean and South American lineage  
Puerto Rico 2010 epidemic  
(~ 1994 – present)


Amino acid changes  
V55I conservative EDII  
M297T non-conservative EDIII

Caribbean and South America  
Puerto Rico epidemics (1994-1995 and 1998)

Early American isolates (1980s)



# DENV-1 Central American lineage



## United State of America

Florida

Mexico

Nicaragua

Costa Rica

Google earth


introductionautochthonous

Santiago, 2014 unpublished


G.A. Santiago 2013

© 2013 Cnes/Spot Image  
Data SIO, NOAA, U.S. Navy, NGA, GEBCO  
Image © 2013 TerraMetrics  
Image U.S. Geological Survey


Imagery Date: 12/31/1969 20°13'03.20"N 89°42'52.76"W elev 253 ft eye alt 2157.41 mi



# Alphavirus Evolution



# History of Chikungunya Virus Emergence





## ECSA lineage

## Asian lineage

## Indian Ocean Lineage

# SARS-CoV-2 Genetic Characterization



<https://www.gisaid.org/phylodynamics/global/nextstrain/>

**> 3,645,340 sequences submitted to GISAID**

<b>Country/Territory</b>	<b>Alpha</b>	<b>Beta</b>	<b>Gamma</b>	<b>Delta</b>
Anguilla	Yes	No	No	Yes
Antigua and Barbuda	Yes	Yes	Yes	Yes
Argentina	Yes	Yes	Yes	Yes
Aruba	Yes	Yes	Yes	Yes
Bahamas	Yes	No	Yes	Yes
Barbados	Yes	No	Yes	Yes
Belize	Yes	No	Yes	Yes
Bermuda	Yes	Yes	No	Yes
Bolivia	Yes	No	Yes	No
Bonaire	Yes	No	Yes	Yes
British Virgin Islands	Yes	No	Yes	Yes
Brazil	Yes	Yes	Yes	Yes
Canada	Yes	Yes	Yes	Yes
Cayman Islands	Yes	Yes	Yes	Yes
Chile	Yes	Yes	Yes	Yes
Colombia	Yes	No	Yes	Yes
Costa Rica	Yes	Yes	Yes	Yes
Cuba	Yes	Yes	No	Yes
Curacao	Yes	Yes	Yes	Yes
Dominica	Yes	No	No	Yes
Dominican Republic	Yes	No	Yes	No
Ecuador	Yes	No	Yes	Yes
El Salvador	Yes	No	Yes	Yes
Falkland Islands	Yes	Yes	No	No
French Guiana	Yes	Yes	Yes	Yes
Grenada	Yes	No	No	Yes
Guadeloupe	Yes	Yes	Yes	Yes
Guatemala	Yes	yes	Yes	Yes
Guyana	No	No	Yes	yes
Haiti	Yes	No	Yes	Yes
Honduras	Yes	No	Yes	Yes
Jamaica	Yes	No	No	Yes
Martinique	Yes	Yes	Yes	Yes
Mexico	Yes	Yes	Yes	Yes
Montserrat	Yes	No	Yes	Yes
Panama	Yes	Yes	Yes	Yes
Paraguay	yes	No	Yes	Yes
Peru	Yes	No	Yes	Yes
Puerto Rico	Yes	Yes	Yes	Yes
Saba	No	No	No	Yes
Saint Barthélemy	Yes	No	No	No
Saint Kitts and Nevis	No	No	No	Yes
Saint Lucia	Yes	No	No	Yes
Saint Martin	Yes	Yes	No	No
St Vincent and the Grenadines	No	No	Yes	Yes
Saint Pierre et Miquelon	No	No	No	Yes
Sint Maarten	Yes	Yes	yes	Yes
Suriname	Yes	Yes	Yes	Yes
Trinidad and Tobago	Yes	No	Yes	Yes
Turks and Caicos	Yes	No	Yes	Yes
United States of America	Yes	Yes	Yes	Yes
Uruguay	Yes	Yes	Yes	Yes
Venezuela	Yes	No	Yes	Yes
Virgin Islands (US)	Yes	Yes	No	Yes

**54 / 56 Countries and Territories have detected at least 1 VOC (September 20)**

**Alpha = 49**


**Beta = 25**

**Gamma = 40**

**Delta = 52**

# Regular update on variants at PAHO Region


## PAHO Region




Dashboard developed by PAHO-IMST

# Regular update on variants at PAHO Region


Caribbean Subregion




North America Subregion



Central America Subregion



South America Subregion



Dashboard developed by Patrick Biche, PAHO-IMST

Dashboard developed by PAHO-IMST

# SARS-CoV-2 Genomic Surveillance Network

## Challenges...

- Strengthen genomic surveillance in the Region through the PAHO Genomic Surveillance Network is a Priority
- Important gaps in sequencing capacity:
  - Too expensive
  - Sustainability (*do we need sequencing in each country?*)
  - Requires specific expertise
  - Shipping of samples: expensive / customs and exportation process is difficult
- Screening protocols may complement the surveillance

# SARS-CoV-2 Genomic Surveillance Network

## Challenges...

- Standardized strategies remain a challenge: Sequencing vs. Genomic surveillance
  - The concept of “molecular epidemiology” should be integrated in surveillance systems
  - Clear surveillance objectives: contact tracing, circulation patterns, clusters in specific population, changes in pathogenesis...
- Surveillance is not only to detect VOI/VOC (political pressures...)

# Gracias!!

**PAHO-IMST**  
**Emerging Viruses**  
**Laboratory Response Team**



Pan American  
Health  
Organization



World Health  
Organization  
REGIONAL OFFICE FOR THE Americas